JNJ

234.5

+0.47%↑

ISRG

478.9

+0.04%↑

ABT

108.4

-0.28%↓

RDY

14.02

+1.37%↑

NEOG

10.55

+2.83%↑

JNJ

234.5

+0.47%↑

ISRG

478.9

+0.04%↑

ABT

108.4

-0.28%↓

RDY

14.02

+1.37%↑

NEOG

10.55

+2.83%↑

JNJ

234.5

+0.47%↑

ISRG

478.9

+0.04%↑

ABT

108.4

-0.28%↓

RDY

14.02

+1.37%↑

NEOG

10.55

+2.83%↑

JNJ

234.5

+0.47%↑

ISRG

478.9

+0.04%↑

ABT

108.4

-0.28%↓

RDY

14.02

+1.37%↑

NEOG

10.55

+2.83%↑

JNJ

234.5

+0.47%↑

ISRG

478.9

+0.04%↑

ABT

108.4

-0.28%↓

RDY

14.02

+1.37%↑

NEOG

10.55

+2.83%↑

Search

Guardant Health Inc

Aperta

SettoreSettore sanitario

105.4 -5.69

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

101.79

Massimo

112.31

Metriche Chiave

By Trading Economics

Entrata

7.2M

-93M

Vendite

33M

265M

Margine di Profitto

-34.965

Dipendenti

1,999

EBITDA

6.6M

-82M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+11.69% upside

Dividendi

By Dow Jones

Utili prossimi

19 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

5.9B

15B

Apertura precedente

111.09

Chiusura precedente

105.4

Notizie sul Sentiment di mercato

By Acuity

50%

50%

152 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Guardant Health Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 feb 2026, 23:11 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Utili

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisizioni, Fusioni, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Discorsi di Mercato

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Utili

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Utili

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Utili

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Utili

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Utili

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Utili

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Utili

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Discorsi di Mercato

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Utili

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Utili

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Utili

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Confronto tra pari

Modifica del prezzo

Guardant Health Inc Previsione

Obiettivo di Prezzo

By TipRanks

11.69% in crescita

Previsioni per 12 mesi

Media 128.33 USD  11.69%

Alto 175 USD

Basso 105 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Guardant Health Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

18

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

38.86 / 47.41Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

152 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat